Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM NASDAQ:ALVR NASDAQ:FNCH NASDAQ:ONCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.60$4.59$2.33▼$36.00$7.04M0.9864,820 shs30,782 shsALVRAlloVir$3.89-9.1%$2.97$7.96▼$24.15$19.62M0.6315,685 shs214,178 shsFNCHFinch Therapeutics Group$12.40-2.1%$12.59$10.15▼$15.85$19.91M1.22,172 shs1,614 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%+4.84%+1.17%-71.55%-91.61%ALVRAlloVir-9.11%-15.80%+70.61%+47.35%-77.64%FNCHFinch Therapeutics Group0.00%-2.36%-2.67%-9.82%+5.53%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.60$4.59$2.33▼$36.00$7.04M0.9864,820 shs30,782 shsALVRAlloVir$3.89-9.1%$2.97$7.96▼$24.15$19.62M0.6315,685 shs214,178 shsFNCHFinch Therapeutics Group$12.40-2.1%$12.59$10.15▼$15.85$19.91M1.22,172 shs1,614 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%+4.84%+1.17%-71.55%-91.61%ALVRAlloVir-9.11%-15.80%+70.61%+47.35%-77.64%FNCHFinch Therapeutics Group0.00%-2.36%-2.67%-9.82%+5.53%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.50Strong Buy$275.0010,476.92% UpsideALVRAlloVir 0.00N/AN/AN/AFNCHFinch Therapeutics Group 0.00N/AN/AN/AONCESpark Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONCE, ALVR, FNCH, and AIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AIMAIM ImmunoTechMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$121K58.21N/AN/A$0.20 per share13.00ALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AONCESpark Therapeutics$64.72M0.11N/AN/A$13.15 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.68N/AN/AN/A-12,594.21%-421.73%-147.54%N/AALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AONCESpark Therapeutics-$78.82M-$2.11N/AN/AN/A-358.41%-59.10%-33.13%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AALVRAlloVirN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AONCESpark TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75ALVRAlloVirN/A86.7886.78FNCHFinch Therapeutics GroupN/A3.873.87ONCESpark Therapeutics0.354.674.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%ALVRAlloVir66.05%FNCHFinch Therapeutics Group21.77%ONCESpark Therapeutics88.37%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%ALVRAlloVir32.07%FNCHFinch Therapeutics Group44.90%ONCESpark Therapeutics6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech202.71 million68.74 millionNot OptionableALVRAlloVir1105.04 million3.43 millionOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataONCESpark Therapeutics36838.52 millionN/ANo DataONCE, ALVR, FNCH, and AIM HeadlinesRecent News About These CompaniesHemophilia B Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsightSeptember 9, 2025 | theglobeandmail.comSpark layoffs won’t derail Philadelphia’s biotech surge, city official saysMay 10, 2025 | technical.lyTHow Spark's layoffs could affect University City real estateApril 11, 2025 | bizjournals.comDespite Spark's massive layoffs, co-founder Jeff Marrazzo says its legacy will endureApril 9, 2025 | bizjournals.comSpark Therapeutics files notice to lay off 300 employees this yearApril 5, 2025 | technical.lyTSpark Therapeutics Cuts 298 Employees as Part of ReorganizationApril 4, 2025 | biospace.comBSpark Therapeutics is laying off 337 people, more than half its workforce, starting in MayApril 3, 2025 | msn.comDoes the Spark Therapeutics writedown undermine Philly’s biotech swagger?March 18, 2025 | technical.lyTRoche to buy gene therapy firm Spark for $4.8 billionMarch 13, 2025 | pharmaphorum.comPRoche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy UnitMarch 12, 2025 | biospace.comBSpark Therapeutics, a Philly biotech pioneer, is being restructured amid financial write-downsMarch 4, 2025 | msn.comPfizer shelves Beqvez, a Spark Therapeutics developed productFebruary 24, 2025 | bizjournals.comSpark Therapeutics co-founder back at the helm of a Philadelphia gene therapy companyJanuary 14, 2025 | bizjournals.comSpark reassures on safety of haemophilia gene therapyDecember 25, 2024 | pharmaphorum.comPRoche mothballs another hemophilia A gene therapy under Spark amid plans to debut new hematologic assetDecember 17, 2024 | fiercebiotech.comFHow ADHD wired me for scientific discoveryNovember 12, 2024 | statnews.comSHuntington Study Group (HSG) Conference 2024 – Day 1November 11, 2024 | en.hdbuzz.netEBitcoin breaks $81,000 for first time on Trump trades; UK government sells £1bn of NatWest shares – business liveNovember 11, 2024 | msn.comMeet the contenders: Vote for the winners of Philly’s 2024 Technical.ly AwardsNovember 7, 2024 | technical.lyTDenver police investigate deadly hit-and-run at South Sheridan and Evans AvenueNovember 6, 2024 | yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Tariff-Proof Retailers Making New All-time HighsBy Dan Schmidt | September 1, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025Palantir Insider Selling: Risk Signal or Normal Activity?By Chris Markoch | September 4, 2025Vanguard’s VUG ETF: The Ultimate Growth ETF for Your PortfolioBy Jeffrey Neal Johnson | September 11, 2025Analyst Upgrades Strengthen Microsoft’s Long-Term OutlookBy Chris Markoch | September 10, 2025ONCE, ALVR, FNCH, and AIM Company DescriptionsAIM ImmunoTech NYSE:AIM$2.60 0.00 (0.00%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$2.59 -0.01 (-0.38%) As of 09/12/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.AlloVir NASDAQ:ALVR$3.89 -0.39 (-9.11%) As of 09/12/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Finch Therapeutics Group NASDAQ:FNCH$12.40 -0.27 (-2.13%) As of 09/12/2025 03:50 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Spark Therapeutics NASDAQ:ONCESpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
